As of December 31, 2023, cash, cash equivalents and marketable securities totaled $306.1 million, compared to cash, cash equivalents and marketable securities of $193.4 million as of December 31, 2022. This increase is due to the net proceeds from the Company’s public offering of approximately $122 million on July 21, 2023, as well as approximately $30 million from K2 HealthVentures as part of a debt financing of up to $50 million announced in November 2023. Altogether, this runway is now expected to be sufficient to support current clinical and operational activities into the first half of 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS:
- ABOS Earnings this Week: How Will it Perform?
- Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
- Acumen Pharmaceuticals Revises ALTITUDE-AD Study Phase
- Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
- Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
